Brind.

AngioDynamics received FDA clearance for its NanoKnife product, which was reported alongside its stock performance relative to the S&P 500.

2 reports, 2 independent Updated Aug 22

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

AngioDynamics received FDA clearance for its NanoKnife product, which was reported alongside its stock performance relative to the S&P 500.

Who's involved

What this event is mainly about

AngioDynamics (United States)FDA

Keep exploring

The entities involved

AngioDynamics (United States)
company in California City, United States

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Aug 22ZacksReasons to Hold AngioDynamics Stock in Your Portfolio for Now AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optim
Jul 15Business WireAngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth Med Tech franchise delivers third consecutive